Connect with us

Technology

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Published

2 years ago

on

SAN DIEGO, May 24, 2024 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx,” or the “Company”) announced that, at a special meeting (the “Special Meeting”), the Company’s stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin (“AAT”) augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency (“AATD”). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx’s non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. (“New Inhibrx”).

The final voting results will be filed in a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (“SEC”).

Subject to the terms of the definitive agreements announced on January 23, 2024, Sanofi will acquire all outstanding shares of Inhibrx through a merger with an indirect wholly owned subsidiary of Sanofi (the “Merger”), and in turn, each Inhibrx stockholder (a) as of the date of the closing of the Merger will receive: (i) $30.00 per share in cash and (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (b) as of May 17, 2024, will rill receive one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held. In addition, in connection with the transactions, Sanofi will assume and retire Inhibrx’s outstanding third party debt, and New Inhibrx will be funded with at least $200 million in cash, with Sanofi retaining an equity interest in New Inhibrx of 8% of outstanding shares of New Inhibrx common stock as of the date of the distribution of New Inhibrx shares.

The Company expects to announce consummation of the transactions within the coming days, subject to the satisfaction or waiver of certain customary closing conditions. Upon closing of the transactions, Inhibrx’s common stock will be delisted from The Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Inhibrx will no longer file periodic reports with the SEC on account of the Company’s common stock.

About Inhibrx, Inc.

Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit www.inhibrx.com.

About Sanofi

Sanofi is an innovative global healthcare company, driven by one purpose: chase the miracles of science to improve people’s lives. Sanofi’s team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of its ambitions.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements about Sanofi’s proposed acquisition of the Company and INBRX-101, and the Company’s related spin-off of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109, its existing pipeline and corporate infrastructure, which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the integration of the Company and Sanofi will be more difficult, time consuming or costly than expected; risks and costs relating to the separation of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109 and the consummation of the spin-off in the anticipated timeframe or at all; changes to the configuration of the INBRX-105, INBRX-106 and INBRX-109 businesses included in the separation if implemented; disruption from the transaction making it more difficult to maintain business and operational relationships; risks related to diverting management’s attention from the Company’s ongoing business operation; negative effects of this announcement or the consummation of the proposed transaction on the market price of the Company’s shares of common stock and/or operating results; significant transaction costs; risks associated with the discovery of unknown liabilities prior to or after the closing of the proposed transactions; the risk of litigation and/or regulatory actions related to the proposed transactions or the Company’s business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; the conflicts in the Ukraine and the Middle East; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; and future business combinations or disposals. Important factors, risks and uncertainties that could cause actual results to differ materially from such forward looking statements also include but are not limited to the initiation, timing, progress and results of the Company’s research and development programs as well as the Company’s preclinical studies and clinical trials; the Company’s ability to advance therapeutic candidates into, and successfully complete, clinical trials; the Company’s interpretation of initial, interim or preliminary data from the Company’s clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals, including whether any product candidate, receives approval from the FDA, or similar regulatory authority, for an accelerated approval process; the commercialization of the Company’s therapeutic candidates, if approved; the pricing, coverage and reimbursement of the Company’s therapeutic candidates, if approved; the Company’s ability to utilize the Company’s technology platform to generate and advance additional therapeutic candidates; the implementation of the Company’s business model and strategic plans for the Company’s business and therapeutic candidates; the Company’s ability to successfully manufacture the Company’s therapeutic candidates for clinical trials and commercial use, if approved; the Company’s ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection the Company is able to establish and maintain for intellectual property rights covering the Company’s therapeutic candidates; the Company’s ability to enter into strategic partnerships and the potential benefits of such partnerships; the Company’s estimates regarding expenses, capital requirements and needs for additional financing; the ability to raise funds needed to satisfy the Company’s capital requirements, which may depend on financial, economic and market conditions and other factors, over which the Company may have no or limited control; the Company’s financial performance; the Company’s and the Company’s third party partners’ and service providers’ ability to continue operations and advance the Company’s therapeutic candidates through clinical trials and the ability of the Company’s third party manufacturers to provide the required raw materials, antibodies and other biologics for the Company’s preclinical research and clinical trials in light of current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, geopolitical events, natural disasters or extreme weather events; the ability to retain the continued service of the Company’s key professionals and to identify, hire and retain additional qualified professionals; and developments relating to the Company’s competitors and the Company’s industry; and other risks described from time to time in the “Risk Factors” section of its filings with the SEC, including those described in its Annual Report on Form 10-K, as well as its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Additional Information and Where to Find It

In connection with the proposed acquisition, the Company has filed documents with the SEC relating to the proposed acquisition. The definitive proxy statement was filed with the SEC on April 26, 2024 and has been mailed to the Company’s stockholders in connection with the proposed acquisition. This communication is not a substitute for the proxy statement or any other document that may be filed by the Company with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION. Investors and security holders may obtain free copies of these documents and other related documents filed with the SEC at the SEC’s website at www.sec.gov or on the Company’s website at https://www.inhibrx.com.

Investor and Media Contact:
Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-inc-stockholders-approve-sale-of-inbrx-101-to-sanofi-302155418.html

SOURCE Inhibrx, Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

HOUSING WORKS CHOSEN AS 2026 BENEFICIARY OF 45TH ANNUAL FRONT RUNNERS NEW YORK LGBTQ+ PRIDE RUN™ 4M

Published

54 minutes ago

on

April 22, 2026

By

JUNE 27 RACE IN CENTRAL PARK WILL RAISE FUNDS FOR HOUSING WORKS’ LIFESAVING SERVICES + ADVOCACY

NEW YORK, April 22, 2026 /PRNewswire/ — Housing Works is proud to announce that it was selected as the beneficiary of the 2026 Front Runners New York LGBTQ+ Pride Run™ 4M hosted by the Front Runners New York and nonprofit New York Road Runners. The iconic 4-mile running event, which kicks off Pride Weekend in NYC, will be held on June 27, 2026, in Central Park.

Since its inception in 1982, the Pride Run has raised more than $300,000 for LGBTQ+ nonprofits as the world’s largest pride charity run. Housing Works was chosen as this year’s beneficiary in recognition of its 35-year history of providing lifesaving healthcare, housing, and justice initiatives for vulnerable New Yorkers. To support this partnership, Housing Works will have a team of over 20 board members, staff, and clients participating in the race under this year’s theme: “Hearts in Motion: United in Every Stride.”

Although the race is sold out, charity bibs are still available. Runners can apply to raise $500 in support of the 2026 Front Runners New York LGBTQ+ Pride Run™4M beneficiary through Front Runners New York and receive a non-complimentary entry to the race.

“We deeply appreciate Front Runners New York in helping us with our fundraising efforts. In the early days, our evidence-based advocacy often met political resistance, making traditional donors hesitant to support our life-saving HIV/AIDS work. Nearly 40 years into the AIDS epidemic, we continue to face budget cuts and limited capital as government administrations shift,” said Matthew Bernardo, President of Housing Works, Inc. “However, the urgency of this fight drives us to innovate. Housing Works is proof that nonprofits can create real, measurable impact for those who need it most.”

“The Pride Run has always been a showing of the strength of our community. Supporting Housing Works this year feels especially meaningful at a time when unity is most needed. Together, every step adds to our shared momentum to support the incredible, lifesaving work that Housing Works provides to our community,” said J Solle, 2026 Front Runners New York LGBTQ+ Pride Run™4M Director.

“When this race began 45 years ago, many of our members faced risks just by signing up to run openly. Today, standing with thousands of runners who sold out this event in hours, we see how far we’ve come,” said Ryan Hallett, President of Front Runners New York. “But progress requires constant action. By partnering with Housing Works, we are honoring our history of activism and ensuring that our strides in Central Park support lifesaving housing and healthcare for the most vulnerable members of our community.”

“For more than 40 years, New York Road Runners has teamed up with Front Runners New York to host the LGBTQ+ Pride Run in celebration of this incredible community,” said Rob Simmelkjaer, New York Road Runners CEO. “Now a marquee event during Pride weekend in New York City, we’re excited to unite the running community once again and help raise awareness and funds for Housing Works’s critical work.”

What: The 2026 LGBTQ+ Pride Run

When: Saturday, June 27, 2026
            Race Start | 8AM

Where: Central Park

Website: https://frny.org/pride-run

For more information about Housing Works, visit housingworks.org. Follow Housing Works on Facebook and Instagram. 

About Housing Works:
For more than three decades, Housing Works has been at the forefront of the movement to end AIDS and homelessness and fight for the rights and dignity of some of the most marginalized populations. Housing Works was founded in 1990 as the housing committee of ACT UP and is now a leading provider of housing and lifesaving services to low-income individuals affected by HIV/AIDS and other chronic illnesses, including LGBTQ+ youth, the transgender community, immigrants, people experiencing substance use, and formerly incarcerated New Yorkers. Housing Works’ integrated healthcare, supportive housing portfolio, wraparound services, and relentless advocacy are supported by innovative social enterprise: nine Thrift Shops throughout Manhattan and Brooklyn, its iconic Bookstore & Cafe in Soho, and most recently, New York’s first adult-use dispensary. In the year ahead, amid challenging headwinds from the federal government, Housing Works continues to expand its services and fight for what is right for those who need our help the most, bridging communities in building a more compassionate and equitable world.

About Front Runners New York:
Front Runners New York (FRNY) is New York City’s LGBTQ+ running club. The club was founded in 1979 and has grown to over 1100 members annually. FRNY’s mission is to provide encouragement and support to LGBTQ+ adults and their supporters who are interested in running and running-related activities. FRNY has created a social running community focused on health and fitness that is welcoming to all New Yorkers. FRNY offers a robust, inclusive membership experience. FRNY is a 501(c)(3) non-profit organization incorporated in the state of New York. For more information, visit frny.org.

About New York Road Runners (NYRR):
A New York City-based nonprofit, New York Road Runners’ vision is to build healthier lives and stronger communities through the transformative power of running—serving more than half a million people annually through its races, free community events, youth running initiatives, and school-based programs across the five boroughs. During its nearly 70 years, New York Road Runners has grown from a local running club to the world’s premier community running organization, producing more than 60 adult and youth races each year, including the TCS New York City Marathon. Held the first Sunday each November, the TCS New York City Marathon features more than 50,000 runners—from the world’s best professional athletes to a vast range of runners across experience levels, ages, genders, abilities, and backgrounds. To learn more, visit www.nyrr.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/housing-works-chosen-as-2026-beneficiary-of-45th-annual-front-runners-new-york-lgbtq-pride-run-4m-302749363.html

SOURCE Housing Works

Continue Reading

Technology

City of Bradenton Launches Accela ePermitHub Digital Plan Room, Advancing Integrated Digital Plan Review

Published

54 minutes ago

on

April 22, 2026

By

SAN RAMON, Calif., April 22, 2026 /PRNewswire/ — The City of Bradenton, FL has launched the Accela® ePermitHub Digital Plan Room™, marking an important milestone in the City’s ongoing efforts to modernize plan review and streamline the permitting process for both staff and applicants.

This launch represents a significant shift for Bradenton, which previously relied on a plan review approach that required staff to navigate multiple systems and complete several manual steps to accomplish a single task. With Accela’s ePermitHub Digital Plan Room, the City now benefits from a fully integrated digital plan review experience, bringing plan review directly into Accela and simplifying workflows for both staff and applicants.

“After our previous experience, we were looking for a solution that truly worked with our permitting system—not alongside it,” said Dana Winters, Building Manager for the City of Bradenton. “With Accela’s ePermitHub, plan review is part of the same system our teams already use every day. It reduces extra steps, eliminates duplicate work, and makes the process much easier for staff to understand and manage.”

Under the City’s prior setup, staff often had to move between systems, log in separately, and repeat actions to keep plan review and permitting records aligned. Accela’s ePermitHub replaces that fragmented experience with a single, streamlined workflow—automating previously manual steps and improving reliability across the review process.

Bradenton serves a population of approximately 58,000 residents and is an active permitting jurisdiction across building and planning disciplines. The transition to ePermitHub was also well received by applicants, who benefit from a simpler, more consistent submission and review experience.

“This launch reflects the progress agencies are making toward more connected, end‑to‑end digital permitting,” said Maykel Martin, Vice President, Technology Product Management, Accela. “By adopting a plan review solution that is native to Accela, Bradenton is improving efficiency for staff while delivering a more consistent experience for applicants.”

The City’s project team was led by Theresa Armstrong (IT), Dana Winters (Building) and Jamie Schindewolf (Planning), who partnered closely with Accela throughout the implementation, bringing a shared focus on delivering the best outcomes for their customers and achieving a smooth, successful deployment.

For media inquiries, please contact:
Media@accela.com

About Accela®

Accela® is a leading provider of cloud-based software solutions, empowering local and state governments to drive efficiency and modernization. Accela offers both a configurable platform and out-of-the-box civic applications for core processes including permitting, licensing, and code enforcement. Accela assists agencies in streamlining workflows, reducing manual tasks, and improving service delivery. With a commitment to end-to-end support, Accela is a trusted partner to over 600 agencies and jurisdictions worldwide. For more information, please visit www.accela.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/city-of-bradenton-launches-accela-epermithub-digital-plan-room-advancing-integrated-digital-plan-review-302749920.html

SOURCE Accela

Continue Reading

Technology

Axonic Insurance Annuities, Built for Banks, Broker-Dealers and RIAs, Now Available through WealthVest.

Published

54 minutes ago

on

April 22, 2026

By

Financial professionals can now secure a competitive 3-year fixed annuity rate and crediting strategies from Deutsche Bank, S&P Global, and Nasdaq through their WealthVest wholesaler and Axonic Insurance.

BOZEMAN, Mont., April 22, 2026 /PRNewswire-PRWeb/ — WealthVest, a leading wholesaler of annuities to financial professionals, has announced a strategic distribution partnership today with Axonic Insurance (AXI), a global annuity and insurance platform. WealthVest will begin offering a suite of curated, highly competitive annuity products from Axonic Insurance to their network of banks, credit unions, broker-dealers and registered investment advisers across the United States.

“We’re excited to align with a team that shares our commitment to delivering differentiated solutions and supporting financial professionals with the tools and opportunities they need to better serve their clients,” said Les Sutherland, Chief Distribution Officer at Axonic Insurance.

“We’re excited to bring the Axonic Insurance suite of solutions to the marketplace,” said Matt Hamann, National Sales Manager at WealthVest. “By combining the strength of our distribution team with AXI’s competitive offerings, we’re well positioned to drive growth and expand access across banks, broker-dealers, and RIAs. Through our education-first approach, we’re committed to supporting financial professionals with practical solutions that help their clients navigate retirement with confidence.”

Through the partnership, Axonic Insurance aims to better support financial advisors and investment adviser representatives in building a solid foundation of protection and growth for their clients’ retirement. WealthVest will align their well-regarded, client-first coaching and wholesaling model with Axonic Insurance’s highly competitive annuities to help financial professionals stay up to date on market trends and determine the best annuity to address their clients’ retirement needs.

“Partnering with WealthVest marks an important step forward in expanding AXI’s reach across the bank, broker-dealer, and RIA channels,” said Les Sutherland, Chief Distribution Officer at Axonic Insurance. “We’re excited to align with a team that shares our commitment to delivering differentiated solutions and supporting financial professionals with the tools and opportunities they need to better serve their clients.”

The suite of annuities is designed specifically for advisors and IARs to help them deliver competitive guaranteed rates of return across 2-, 3-, 5-, 7- and 10-year surrender period options; strong marketing participation; 100% principal protection and systematic income withdrawals to their clients. The annuities are available in forty-three states and the District of Columbia, and include the:

Incline MYGA: Featuring 5.25% Guaranteed for 3-Years with Initial Premiums of $100,000 or Greater1HighLine FIA: Offering 1- and 2-year point-to-point cap, participation, and fixed rate crediting strategiesHighLine FIA PLUS: Includes a 9% Premium Bonus Rider on the 5-Year2

WealthVest’s team of dedicated wholesalers and annuity case managers will serve as the main point of contact for financial advisors and IARs interested in Axonic Insurance’s annuities across 5 US regions. The team has partnered with thousands of advisors, providing annuity planning technology, retirement income planning, practice management, market and industry trends and annuity case management.

Launched in 2024, Axonic Insurance is an annuity and insurance platform delivering institutionally managed retirement products through a fully integrated model spanning product design, distribution, issuance, and servicing. Axonic Insurance is supported by Axonic Capital, an investment management firm with $8 billion in assets under management specializing in structured credit and commercial and residential real estate debt and equity. Axonic Insurance’s suite of annuities is issued by AmFirst Insurance Company (“AmFirst”), an A- (Excellent) financial strength rated company by AM Best3.

Advisors and IARs interested in learning more about Axonic Insurance and their suite of annuities can connect with their wholesaler at www.wealthvest.com/axonic-insurance or call the WealthVest Sales Desk at 1-833-299-8750.

1 Rate shown is effective March 27, 2026 and subject to change. Rate only applies to the Incline MYGA 3-year plan with initial premiums of $100,000 or greater, issued by AmFirst Insurance Company (“AmFirst”) and offered by Axonic Insurance Services LLC (“Axonic”). Additional rates available.

2 At the time of issuance, the Premium Bonus is credited to your Account Value, providing immediate access to additional funds to allocate into the various crediting strategies. The Premium Bonus is calculated as a percentage of the initial premium and becomes a permanent component of the annuity’s Accumulation Value. All Premium Bonuses are subject to a Vesting Schedule, under which the Contract Value and the Cash Surrender Value increase annually as the bonus amount vests over time. Please refer to the HighLine FIA Rate Sheet for Premium Bonus amounts and Contract details.

3 AM Best affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings of “A-” (Excellent) of AmFirst Insurance Company on August 29, 2025.

ABOUT WEALTHVEST

WealthVest is a leading wholesaler of fixed, fixed-indexed, and registered index-linked annuities to financial professionals. We’re a partner to thousands of advisors by providing annuity planning technology, retirement income planning, practice management, market and industry trends and annuity case management. Their team of dedicated wholesalers and annuity case managers helps advisors provide the best annuity outcomes. Follow us on Facebook and LinkedIn or visit wealthvest.com.

ABOUT AXONIC INSURANCE

Axonic Insurance (AXI) is a fast-growing annuity and insurance platform delivering institutionally managed retirement products through a fully integrated model spanning product design, distribution, issuance, and servicing. AXI combines modern insurance capabilities with disciplined asset management and rigorous risk oversight to drive scalable, sustainable growth. AXI’s suite of annuities includes Multi-Year Guaranteed Annuities (MYGAs) and Fixed Indexed Annuities (FIAs), distributed through IMOs, Banks, Broker-Dealers, and Registered Investment Advisers (RIAs), while strengthening profitability through operational efficiency, pricing discipline, and balance sheet resilience. AXI’s strategy prioritizes durability — balancing growth, capital strength, and earnings to support long-term value creation and financial stability.

ABOUT AXONIC CAPITAL

Founded in 2010, Axonic Capital is a New York-based alternative investment manager with $8 billion in assets under management. The firm has deep expertise in structured credit, commercial and residential real estate debt and equity, and systematic fixed income. Axonic’s flexible capital base includes private limited partnerships, separate accounts, insurance company mandates, and publicly listed fund structures. For additional information, visit axoniccap.com.

ABOUT S&P DOW JONES INDICES

Since 1896, S&P DJI have provided innovative index solutions backed by robust methodologies and strong governance. Today, S&P Dow Jones Indices is the world’s largest provider of financial market indices, offering iconic solutions and unparalleled expertise across asset classes and geographies. With more exchange partnerships and more assets invested in products based on our indices than any other index provider, S&P DJI is a critical link in capital markets and the global financial ecosystem.

ABOUT NASDAQ GLOBAL INDEXES

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide. 

ABOUT DEUTSCHE BANK

Deutsche Bank provides retail and private banking, corporate and transaction banking, lending, asset and wealth management products and services as well as focused investment banking to private individuals, small and medium-sized companies, corporations, governments and institutional investors. Deutsche Bank is the leading bank in Germany with strong European roots and a global network. Deutsche Bank’s FIG Structuring & Solutions business structures and arranges bespoke capital and financing transactions for its global FIG client base.

Media Contact

Jackson Bolstad, WealthVest, 1 406-272-3759, jbolstad@wealthvest.com, www.wealthvest.com

Les Sutherland, Axonic Insurance, lsutherland@axonicinsurance.com, https://axonicinsurance.com/

Twitter, Facebook, LinkedIn

View original content:https://www.prweb.com/releases/axonic-insurance-annuities-built-for-banks-broker-dealers-and-rias-now-available-through-wealthvest-302750101.html

SOURCE WealthVest

Continue Reading

Trending